Ripple Foods specializes in producing high-quality, dairy-free milk alternatives that prioritize nutrition and taste. Their products are designed to be high in protein, offering eight times the protein found in almond milk while containing half the sugar of traditional dairy milk. Additionally, Ripple's beverages are rich in bioavailable calcium, providing 50% more than regular milk, and are a good source of potassium and omega-3 fatty acids. With a focus on delivering a creamy texture that enhances the drinking experience, Ripple aims to provide a satisfying alternative for those seeking non-dairy options without sacrificing flavor or nutritional value.
Accera, Inc. is a clinical stage biotechnology company based in Broomfield, Colorado, focused on developing therapies for central nervous system disorders, particularly neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Founded in 2001, the company utilizes a proprietary scientific platform to address significant unmet medical needs in brain health. One of its key products is Ketasyn, a therapeutic molecule aimed at treating Alzheimer’s disease, Parkinson’s disease, and age-associated memory impairment. Accera operates as a subsidiary of Nestlé S.A.
XOLUTION GmbH is a Munich-based company that specializes in the manufacture of re-closable ends for beverage cans. The company has developed the XO resealable can, which has garnered recognition for its innovative design, winning a Silver Award in the Prototype category at the Can of the Year Awards in Dubai in 2009. The product has undergone extensive market research and field testing, positioning XOLUTION as a potential leader in the beverage packaging industry. Under the leadership of Chief Executive Marc von Rettberg and Vice President of R&D Christian Bratsch, the company has established product design guidelines focused on ease of use for consumers, seamless integration for beverage fillers, and improved branding options for beverage brands, all at a reasonable cost. XOLUTION's rapid prototyping and testing capabilities, developed at their Salzburg R&D Center, further enhance their competitive edge. The company is dedicated to converting innovative concepts into technologically advanced products that will significantly impact the canned beverage market.
Cognoptix is creating and developing an innovative, non-invasive eye test to assist in the early diagnosis of Alzheimer's Disease. Cognoptix's goal is to provide clinicians with a quick, predictive, reliable, inexpensive, and widely available test, enabling early diagnosis and treatment.
The company was founded in 2001 and headquartered in Marlborough, Massachusetts.
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
Phagenesis Limited is focused on developing medical device technology aimed at treating dysphagia, a condition that impairs swallowing, often resulting from strokes or brain injuries. The company's primary product, Phagenyx, consists of a base station that delivers electrical stimulations to the patient and records pertinent information, along with a catheter that is introduced through the nose to stimulate the pharynx. This innovative approach leverages the brain's ability to relearn lost functions through neuroplasticity, effectively aiding patients in regaining control over their swallowing mechanisms. Founded in 2007 and based in Manchester, United Kingdom, Phagenesis emphasizes research and evidence-based solutions, with foundational work led by Professor Shaheen Hamdy of the University of Manchester, whose findings have been published in prestigious medical journals.
Phosphate Therapeutics is an independent specialty pharmaceutical company based in the UK, dedicated to developing mineral-derived hospital pharmaceuticals. The company is currently focused on advancing its phosphate binder, PT20, which is designed to treat hyperphosphataemia, a condition characterized by elevated phosphate levels in the blood, often associated with chronic kidney disease (CKD). PT20 is intended for use in patients with both dialysis-dependent and dialysis-independent forms of CKD. The company aims to utilize its resources to complete the Phase 2 development of this drug, having acquired global rights from the Medical Research Council. Through its innovative approach, Phosphate Therapeutics seeks to address the critical need for effective treatments in patients suffering from systemic phosphate accumulation related to late-stage renal disease.
Phagenesis Limited is focused on developing medical device technology aimed at treating dysphagia, a condition that impairs swallowing, often resulting from strokes or brain injuries. The company's primary product, Phagenyx, consists of a base station that delivers electrical stimulations to the patient and records pertinent information, along with a catheter that is introduced through the nose to stimulate the pharynx. This innovative approach leverages the brain's ability to relearn lost functions through neuroplasticity, effectively aiding patients in regaining control over their swallowing mechanisms. Founded in 2007 and based in Manchester, United Kingdom, Phagenesis emphasizes research and evidence-based solutions, with foundational work led by Professor Shaheen Hamdy of the University of Manchester, whose findings have been published in prestigious medical journals.
MSI Methylation Sciences Inc. is a biotechnology company based in Canada that focuses on developing oral and small molecule therapies for the adjunctive treatment of Major Depressive Disorder (MDD). Founded in 2007, the company is known for its flagship product, Strada, which is an orally administered therapy aimed at alleviating symptoms of depression in MDD patients. In addition to its therapeutic developments, MSI Methylation Sciences also markets S-Adenosyl Methionine, a prescription drug used as a dietary supplement. The company's work is centered around addressing mental health challenges through innovative treatment options.
Shield Therapeutics is an independent specialty pharmaceutical company based in Wollerau, Switzerland, dedicated to developing and commercializing late-stage, hospital-focused pharmaceuticals that meet significant unmet medical needs. The company is particularly focused on its lead product, Feraccru, which is designed for the treatment of iron deficiency anemia associated with conditions like inflammatory bowel disease and chronic kidney disease. Additionally, Shield Therapeutics is advancing PT20, a product aimed at treating hyperphosphatemia, which is nearing completion in its development process. The company primarily generates revenue from the Feraccru segment, highlighting its commitment to addressing critical health challenges in the hospital setting.
Accera, Inc. is a clinical stage biotechnology company based in Broomfield, Colorado, focused on developing therapies for central nervous system disorders, particularly neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Founded in 2001, the company utilizes a proprietary scientific platform to address significant unmet medical needs in brain health. One of its key products is Ketasyn, a therapeutic molecule aimed at treating Alzheimer’s disease, Parkinson’s disease, and age-associated memory impairment. Accera operates as a subsidiary of Nestlé S.A.
CMP Therapeutics, Ltd. is a biopharmaceutical company based in Bicester, United Kingdom, specializing in the development of chitin microparticles for targeting macrophages and dendritic cells in the nasal and respiratory tract. Founded in 2004, the company focuses on creating a nasal spray designed to treat allergic rhinitis and enhance natural resistance to influenza and other respiratory pathogens. Additionally, CMP Therapeutics' chitin microparticles serve as an adjuvant in nasal vaccines, providing a means for patients to prevent and treat allergy-related conditions, asthma, and other infectious diseases through intranasal delivery systems or functional foods.
Tanfield Direct is an online provider of natural foods.
MooBella has developed a revolutionary, disruptive technology that has the potential to transform and expand the nearly $60 billion ice cream industry. It enables instantaneous aeration, flavoring and freezing of ice cream into scoops of premium hard ice cream within seconds, and thereby eliminating the frozen supply chain.
Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.
Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.
Accera, Inc. is a clinical stage biotechnology company based in Broomfield, Colorado, focused on developing therapies for central nervous system disorders, particularly neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Founded in 2001, the company utilizes a proprietary scientific platform to address significant unmet medical needs in brain health. One of its key products is Ketasyn, a therapeutic molecule aimed at treating Alzheimer’s disease, Parkinson’s disease, and age-associated memory impairment. Accera operates as a subsidiary of Nestlé S.A.
Cognoptix is creating and developing an innovative, non-invasive eye test to assist in the early diagnosis of Alzheimer's Disease. Cognoptix's goal is to provide clinicians with a quick, predictive, reliable, inexpensive, and widely available test, enabling early diagnosis and treatment.
The company was founded in 2001 and headquartered in Marlborough, Massachusetts.
Steaz is a brand of organic green tea beverages made with ingredients you can feel good about. Since 2002, Steaz has provided fans with healthy, high-quality beverages while maintaining strong, socially responsible relationships with the company’s ingredient partners around the world. Their pride is anchored in their organic certification and dedication to fair trade and support for sustainable farming around the world. Steaz is available in three healthy and delicious product lines – iced green teas, energy drinks and cactus water beverages. Find your flavor and start sipping on certified goodness.
GC-Rise Pharmaceutical Co., Ltd. is a solely-foreign-owned enterprise invested by INVENTAGES, a famous European investment group engaged in healthcare industry. Taking “Devoted to human healthcare and a better life” as our mission, the company makes full use of the business networks of our strategic cooperation partner in America, Europe and Japan, their affluent experiences in clinical development, clinical trials and registration in China, and their abundant strength in commercial distribution, hospital sale, marketing, so as to provide novel, safe, and highly efficient medical products and treatment ideas for Chinese patients.
Food Quality Sensor International, Inc. is a sensor technology company based in Lexington, Massachusetts, that specializes in the development and commercialization of real-time devices for measuring food freshness. Founded in 2004, the company offers products such as SensorQ, which assesses the freshness of meat and poultry within their packaging, and SensorfreshQ, a handheld electronic nose designed to detect spoilage in these products. Its clientele spans various sectors, including food processing, grocery distribution, food service, regulatory agencies, defense, and consumer retail markets, highlighting its commitment to enhancing food safety and quality.
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
MooBella has developed a revolutionary, disruptive technology that has the potential to transform and expand the nearly $60 billion ice cream industry. It enables instantaneous aeration, flavoring and freezing of ice cream into scoops of premium hard ice cream within seconds, and thereby eliminating the frozen supply chain.
Phytomedics is committed to quality, technological innovation and research. Their powerful portfolio of overlapping proprietary technologies is targeted to turning green plants into reliable vehicles for discovering and manufacturing proprietary botanical pharmaceuticals and nutraceuticals. NewLeadTM and RhizexTM elicitation and optimization processes greatly enhance the efficacy and reproducibility of plant-derived products and increase the synergy between various chemical components of plant extracts. The Company has developed an efficient and proprietary discovery and lead prioritization process based on high-power bio-informatics, high-tech data mining, efficient activity screening, and an extensive network of international collaborations.
DiObex, Inc. operates as a biotechnology company in the United States. The company develops novel products for the treatment of metabolic disorders, including type-one and type-two diabetes, dyslipidemia, obesity, and diabetic nephropathy. Its products include DIO-901, a very low dose glucagon product that is developed for the reduction of nocturnal hypoglycemia in patients with type-one diabetes; and DIO-902, a cortisol synthesis inhibitor that is developed as a therapy for glucose and cholesterol control in patients with type-two diabetes. DiObex, Inc. was founded in 2003 and is based in San Francisco, California.
Cryolog S.A., established in 2002 and based in Nantes, France, specializes in cold chain management for fresh and ultra-fresh food products. The company designs innovative tools and solutions, notably time temperature integrators (TTI), which are self-adhesive labels. A key product is TOPCRYO, a thermosensitive microbiological tablet that visually indicates the effect of time and temperature on product preservation by changing color from green to red. These TTIs function as biological tracers using food-grade microorganisms to ensure effective monitoring of the cold chain. Cryolog's operations gained new direction in 2014 when it was acquired by CLOCK-T °, with significant backing from CapAgro, a capital investment fund focused on agribusiness innovation.
Private Equity Round in 2007
Seth Goldman, co-founder of Honest Tea, drank a lot of liquids. An active person, Seth was continually in search of the perfect drink to quench his thirst after a run, a game of basketball or between grad school classes. Yet, Seth found most drinks either too sweet or too tasteless. Barry Nalebuff, Seth’s professor at the Yale School of Management, found that he and Seth shared a passion for the idea of a less sweet, but flavorful beverage during a class discussion of a Coke vs. Pepsi case study. They agreed that there were tons of sweet options and lots of watery drinks, but in 1994, there was nothing in between to fill the void. Fast forward to ’97. Seth goes for a run in New York City with a college friend who used to concoct juice drinks with him after class. As they found themselves doing the same beverage mixing after the run, Seth knew then that if he was going to quench his thirst for good, he would have to create the drink himself. He e-mailed Barry to see if he was still excited about the idea. Timing was everything. Barry had just returned from India where he had been analyzing the tea industry for a case study. Among other things, he came away with the impression that the tea many American companies purchased for bottling was the dust and fannings left after whole tea leaves had been brewed. Barry had even come up with a name to describe a bottled tea that was made with real tea leaves–Honest Tea. When Seth heard the name, the simmering idea began to boil–it was the perfect name for an all-natural brand that would strive to create healthy and honest relationships with its customers, suppliers and the environment. Seth took a deep breath, quit his job at Calvert mutual funds, and started brewing batches of tea in his kitchen. Five weeks after taking the plunge, he brought thermoses of tea and a recycled bottle with a mock-up label to Fresh Fields (Whole Foods Market). The buyer ordered 15,000 bottles, and Seth and Barry were in business–if they could figure out how to make that much tea. They did, and they’re still at it 15 years later. In March 2011, The Coca-Cola Company purchased Honest Tea after an initial 40% investment in 2008, which helped expand the distribution of HONEST® beverages. Today, Honest Tea is run as an independent business unit and their HONEST TEA®, HONEST ADE®, HONEST KIDS®, HONEST SPLASH™ and HONEST Fizz beverages can be found in more than 100,000 stores across United States. The dream that took root in Seth’s kitchen in 1998 became a company that just celebrated its 15th anniversary. Seth continues to run the business as the President and TeaEO in Bethesda, MD with the same passion towards health, the environment and social responsibility.
CMP Therapeutics, Ltd. is a biopharmaceutical company based in Bicester, United Kingdom, specializing in the development of chitin microparticles for targeting macrophages and dendritic cells in the nasal and respiratory tract. Founded in 2004, the company focuses on creating a nasal spray designed to treat allergic rhinitis and enhance natural resistance to influenza and other respiratory pathogens. Additionally, CMP Therapeutics' chitin microparticles serve as an adjuvant in nasal vaccines, providing a means for patients to prevent and treat allergy-related conditions, asthma, and other infectious diseases through intranasal delivery systems or functional foods.
Accera, Inc. is a clinical stage biotechnology company based in Broomfield, Colorado, focused on developing therapies for central nervous system disorders, particularly neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Founded in 2001, the company utilizes a proprietary scientific platform to address significant unmet medical needs in brain health. One of its key products is Ketasyn, a therapeutic molecule aimed at treating Alzheimer’s disease, Parkinson’s disease, and age-associated memory impairment. Accera operates as a subsidiary of Nestlé S.A.
Technologie BiolActis (BiolActis) is a Canadian biotechnology company incorporated in 1998. Since its foundation, the entrepreneurs were committed to create novel Biologics meeting well identified needs from the Wellness Industries (Functional Nutrition, Dietary Supplements, Cosmeceuticals and Pharmaceuticals).
TriMed Research, Inc. engages in the research and development of therapeutic products primarily related to mammary gland protein designated as MAA.
DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH).
Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.
The Cavis microcaps has many years’ experience in the field of alginate-based encapsulation and immobilisation. The main focus of their services is encapsulation of additives for the food industry and pet food sectors. Their products are used in food technology as well as in cosmetic and technical applications.
Cryolog S.A., established in 2002 and based in Nantes, France, specializes in cold chain management for fresh and ultra-fresh food products. The company designs innovative tools and solutions, notably time temperature integrators (TTI), which are self-adhesive labels. A key product is TOPCRYO, a thermosensitive microbiological tablet that visually indicates the effect of time and temperature on product preservation by changing color from green to red. These TTIs function as biological tracers using food-grade microorganisms to ensure effective monitoring of the cold chain. Cryolog's operations gained new direction in 2014 when it was acquired by CLOCK-T °, with significant backing from CapAgro, a capital investment fund focused on agribusiness innovation.
SelectX Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery and development of aminoglycoside therapeutics for unmet medical needs. It has built an advanced aminoglycoside drug and other drugs. The company’s advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections.
SelectX Pharmaceuticals Inc. is currently developing a next generation inhaled aminoglycoside antibiotic for drug resistant gram-negative infections in patients with Cystic Fibrosis and other respiratory diseases. The company is based in Boston, Massachusetts.
Phytomedics is committed to quality, technological innovation and research. Their powerful portfolio of overlapping proprietary technologies is targeted to turning green plants into reliable vehicles for discovering and manufacturing proprietary botanical pharmaceuticals and nutraceuticals. NewLeadTM and RhizexTM elicitation and optimization processes greatly enhance the efficacy and reproducibility of plant-derived products and increase the synergy between various chemical components of plant extracts. The Company has developed an efficient and proprietary discovery and lead prioritization process based on high-power bio-informatics, high-tech data mining, efficient activity screening, and an extensive network of international collaborations.